Cerity Partners LLC Has $560,000 Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Cerity Partners LLC raised its stake in Moderna, Inc. (NASDAQ:MRNA) by 106.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 5,626 shares of the company’s stock after purchasing an additional 2,903 shares during the quarter. Cerity Partners LLC’s holdings in Moderna were worth $560,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in MRNA. The Manufacturers Life Insurance Company increased its stake in Moderna by 77.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock valued at $400,367,000 after buying an additional 1,690,341 shares during the period. Invesco Ltd. increased its stake in Moderna by 19.8% in the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after buying an additional 517,683 shares during the period. Wellington Management Group LLP increased its stake in Moderna by 9.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock valued at $579,572,000 after buying an additional 476,201 shares during the period. Bamco Inc. NY increased its stake in Moderna by 4,863.6% in the 3rd quarter. Bamco Inc. NY now owns 426,869 shares of the company’s stock valued at $44,091,000 after buying an additional 418,269 shares during the period. Finally, International Assets Investment Management LLC increased its stake in Moderna by 6,528.9% in the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock valued at $38,552,000 after buying an additional 381,808 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Transactions at Moderna

In other news, President Stephen Hoge sold 2,388 shares of the firm’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16. Following the completion of the transaction, the president now directly owns 1,515,898 shares of the company’s stock, valued at approximately $143,358,473.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, President Stephen Hoge sold 2,388 shares of the firm’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16. Following the completion of the transaction, the president now directly owns 1,515,898 shares of the company’s stock, valued at approximately $143,358,473.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total transaction of $1,550,700.00. Following the transaction, the director now directly owns 2,056,931 shares of the company’s stock, valued at $212,645,526.78. The disclosure for this sale can be found here. In the last three months, insiders sold 109,954 shares of company stock valued at $11,533,976. Company insiders own 15.20% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the topic of several analyst reports. Jefferies Financial Group restated a “buy” rating and set a $125.00 price target on shares of Moderna in a research note on Tuesday, April 9th. William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Oppenheimer upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target on the stock in a research note on Tuesday, January 2nd. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. Finally, HSBC restated a “reduce” rating and set a $86.00 price target (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $126.49.

Moderna Price Performance

Shares of Moderna stock opened at $108.85 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $142.79. The firm has a fifty day moving average price of $101.85 and a two-hundred day moving average price of $93.64. The company has a market cap of $41.68 billion, a PE ratio of -8.77 and a beta of 1.62.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. The firm had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business’s revenue was down 44.9% on a year-over-year basis. During the same period in the prior year, the firm earned $3.61 EPS. Analysts expect that Moderna, Inc. will post -7.51 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.